MarketCap
Facebook
X
Telegram
Adaptimmune Therapeutics plc Operating Cycle | ADAP
Annual Operating Cycle Adaptimmune Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.1 K | 25 | 55 | 26.4 | 6.41 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.1 K | 6.41 | 3.84 K |
Quarterly Operating Cycle Adaptimmune Therapeutics plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 468 | 1.03 K | - | 16.6 | 3.82 | 74.1 | - | 23.4 | 41.7 | 8.77 | - | 11.6 | 15 | 32.9 | - | 144 | 31.8 | 14.6 | - | 10.6 | 12.6 | - | - | 733 | 1.11 K | - | - | 0.43 | 1.94 | 2.22 | - | 0.69 | 5.34 | 26.9 | - | 55.9 | 206 | 11.7 | - | 13.7 | 24.4 | 3.78 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 K | 0.43 | 138 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Incyte Corporation
INCY
|
145 | $ 118.15 | -3.83 % | $ 23.1 B |  USA |
 |
Cocrystal Pharma
COCP
|
78.2 | $ 1.0 | -0.99 % | $ 11.3 M | USA |
 |
Vaccinex
VCNX
|
546 | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
17.9 | - | -19.68 % | $ 18.4 M |  Canada |
 |
Jounce Therapeutics
JNCE
|
2.32 | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
136 | - | - | $ 69.7 B |  Britain |
 |
Zai Lab Limited
ZLAB
|
186 | $ 22.61 | -0.83 % | $ 24.8 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
22.6 | $ 1.72 | -2.56 % | $ 124 M | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Ionis Pharmaceuticals
IONS
|
259 | $ 38.76 | -3.46 % | $ 6.2 B | USA |
 |
CymaBay Therapeutics
CBAY
|
175 | - | - | $ 3.45 B | USA |
 |
Timber Pharmaceuticals
TMBR
|
1.61 | - | - | $ 717 K | USA |
 |
G1 Therapeutics
GTHX
|
52.6 | - | - | $ 370 M | USA |
 |
Theravance Biopharma
TBPH
|
64.5 | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Axon Enterprise
AXON
|
98.8 | $ 379.58 | -10.52 % | $ 29.6 B | USA |
 |
Axsome Therapeutics
AXSM
|
273 | $ 129.19 | -5.7 % | $ 6.43 B | USA |
 |
Karuna Therapeutics
KRTX
|
15.9 | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
52.5 | - | - | $ 756 M | USA |
 |
LogicBio Therapeutics
LOGC
|
9.88 | - | - | $ 229 M | USA |
 |
Merck & Co.
MRK
|
204 | $ 146.9 | -2.29 % | $ 368 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
6 | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
40.3 | - | 0.42 % | $ 213 M | USA |
 |
HOOKIPA Pharma
HOOK
|
3.33 | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
217 | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
84.9 | - | - | $ 109 M | USA |
 |
Otonomy
OTIC
|
112 | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |